DEXCOM, INC. DexCom, Inc. Share Price BOERSE MUENCHEN
Equities
DC4
US2521311074
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.5 EUR | +1.64% |
|
-0.09% | -4.14% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 4.33B 4.01B 340B | Sales 2025 * | 5.15B 4.77B 405B | Capitalization | 46.05B 42.64B 3,620B |
|---|---|---|---|---|---|
| Net income 2024 * | 728M 674M 57.23B | Net income 2025 * | 906M 839M 71.22B | EV / Sales 2024 * | 11 x |
| Net Debt 2024 * | 1.43B 1.33B 113B | Net Debt 2025 * | 994M 921M 78.16B | EV / Sales 2025 * | 9.13 x |
| P/E ratio 2024 * |
64.1
x | P/E ratio 2025 * |
52.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on DexCom, Inc.
More recommendations
More press releases
More news
| 1 week | -0.09% | ||
| Current month | -0.09% | ||
| 1 month | -11.12% | ||
| 3 months | -11.33% | ||
| 6 months | -2.33% | ||
| Current year | -4.14% |
1 week
104.90
110.96
1 month
104.90121.98
3 years
64.38144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 31/10/07 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 31/08/18 |
| Chief Tech/Sci/R&D Officer | 47 | 30/09/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 19/11/09 |
Mark Foletta
BRD | Director/Board Member | 63 | 18/11/14 |
Eric Topol
BRD | Director/Board Member | 69 | 08/07/09 |
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 107.5 | +1.64% |
| 06/06/24 | 105.8 | -2.83% |
| 05/06/24 | 108.9 | +1.66% |
| 04/06/24 | 107.1 | +2.10% |
| 03/06/24 | 104.9 | -2.55% |
Real-time BOERSE MUENCHEN, June 07, 2024 at 08:43 pm
More quotes
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
115.8
USD
Average target price
150.3
USD
Spread / Average Target
+29.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.26% | 187B | |
| +2.05% | 110B | |
| -1.31% | 69.54B | |
| +14.65% | 46.37B | |
| +7.97% | 42.54B | |
| +18.60% | 30.72B | |
| +16.92% | 25.62B | |
| -6.87% | 23.32B | |
| -10.63% | 22.92B |
- Stock Market
- Equities
- DXCM Stock
- DC4 Stock